Korean J Hepatobiliary Pancreat Surg.  2014 Feb;18(1):1-8. 10.14701/kjhbps.2014.18.1.1.

Clinical features and survival outcome of locally advanced extrahepatic cholangiocarcinoma

• Lee SJ
• Kwon W
• Kang MJ
• Jang JY
• Chang YR
• Jung W
• Kim SW

• KMID: 1890073
• DOI: http://doi.org/10.14701/kjhbps.2014.18.1.1

Abstract

BACKGROUNDS/AIMS
Little is known about clinical features and survival outcome in locally advanced unresectable extrahepatic cholangiocarcinoma (EHC). The aim was to investigate the clinical features and the survival outcome in these patients, and to evaluate the role of palliative resections in locally advanced unresectable EHC.
METHODS
Between 1995 and 2007, 280 patients with locally advanced unresectable EHC were identified. Clinical, pathologic, and survival data were investigated. A comparative analysis was done between those who received palliative resection (PR) and those who were not operated on (NR).
RESULTS
The overall median survival of the study population was 10+/-1 months, and the 3- and 5-year survival rates (YSR) were 8.5% and 2.5%, respectively. The median survival, 3- and 5-YSR of PR were 23 months, 32.1% and 13.1%, respectively. For NR, they were 9 months, 3.9% and 0%, which were significantly worse than PR (p<0.001). In univariate analysis, T classification, N classification, tumor location, palliative resection, adjuvant treatment, chemotherapy, and radiation therapy were factors that showed survival difference between PR and NR. Regional lymph node metastasis (RR, 2.084; 95% CI, 1.491-2.914; p<0.001), non-resections (RR, 2.270; 95% CI, 1.497-3.443; p<0.001), and no chemotherapy (RR, 1.604; 95% CI, 1.095-2.349; p=0.015) were identified as risk factors for poor outcome on multivariate analysis.
CONCLUSIONS
Without evidence of systemic disease, palliative resection may provide some survival benefit in selected locally advanced unresectable EHCs and adjuvant treatment may further improve survival outcome.

Keyword

Extrahepatic; Cholangiocarcinoma; Palliative surgery; Survival; Adjuvant therapy

MeSH Terms

Cholangiocarcinoma*
Classification
Drug Therapy
Humans
Lymph Nodes
Multivariate Analysis
Neoplasm Metastasis
Palliative Care
Risk Factors
Survival Rate

Figure

• 

  Fig. 1 A summary of selection of patients eligible for analysis is depicted.

• 

  Fig. 2 The survival outcome of palliative resection (PR) was significantly better than that of non-resection (NR).

• 

  Fig. 3 Comparison of survival outcomes in T3 shows that palliative resection have survival benefit (A). However, this survival benefit of palliative resection is no longer valid in T4 tumors (B).

• 

  Fig. 4 Adjuvant treatment shows significantly improved survival in locally advanced unresectable EHCs (A). Subgroup survival analysis demonstrates that palliative resection is essential to improve the benefit of adjuvant treatment (Adj. Tx) (B).

• 

  Fig. 5 Management algorithm for locally advanced EHC is depicted.

Reference

1. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996; 224:463–473. PMID: 8857851.

2. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford). 2008; 10:77–82. PMID: 18773060.

3. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004; 24:115–125. PMID: 15192785.

4. Vern-Gross TZ, Shivnani AT, Chen K, et al. Survival outcomes in resected extrahepatic cholangiocarcinoma: effect of adjuvant radiotherapy in a surveillance, epidemiology, and end results analysis. Int J Radiat Oncol Biol Phys. 2011; 81:189–198. PMID: 20971573.

5. Seyama Y, Makuuchi M. Current surgical treatment for bile duct cancer. World J Gastroenterol. 2007; 13:1505–1515. PMID: 17461441.

6. Jang JY, Kim SW, Park DJ, et al. Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg. 2005; 241:77–84. PMID: 15621994.

7. Blom D, Schwartz SI. Surgical treatment and outcomes in carcinoma of the extrahepatic bile ducts: the University of Rochester experience. Arch Surg. 2001; 136:209–215. PMID: 11177143.

8. Otani K, Chijiiwa K, Kai M, et al. Outcome of surgical treatment of hilar cholangiocarcinoma. J Gastrointest Surg. 2008; 12:1033–1040. PMID: 18085342.

9. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001; 234:507–517. PMID: 11573044.

10. Witzigmann H, Berr F, Ringel U, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg. 2006; 244:230–239. PMID: 16858185.

11. Schiffman SC, Reuter NP, McMasters KM, et al. Overall survival peri-hilar cholangiocarcinoma: R1 resection with curative intent compared to primary endoscopic therapy. J Surg Oncol. 2012; 105:91–96. PMID: 21815152.

12. Ito F, Agni R, Rettammel RJ, et al. Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann Surg. 2008; 248:273–279. PMID: 18650638.

13. Jarnagin WR, Bowne W, Klimstra DS, et al. Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg. 2005; 241:703–712. PMID: 15849506.

14. Nakeeb A, Tran KQ, Black MJ, et al. Improved survival in resected biliary malignancies. Surgery. 2002; 132:555–563. PMID: 12407338.

15. Kawasaki S, Imamura H, Kobayashi A, et al. Results of surgical resection for patients with hilar bile duct cancer: application of extended hepatectomy after biliary drainage and hemihepatic portal vein embolization. Ann Surg. 2003; 238:84–92. PMID: 12832969.

16. Kosuge T, Yamamoto J, Shimada K, et al. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg. 1999; 230:663–671. PMID: 10561090.

17. Miyazaki M, Ito H, Nakagawa K, et al. Aggressive surgical approaches to hilar cholangiocarcinoma: hepatic or local resection? Surgery. 1998; 123:131–136. PMID: 9481397.

18. Hemming AW, Reed AI, Fujita S, et al. Surgical management of hilar cholangiocarcinoma. Ann Surg. 2005; 241:693–699. PMID: 15849505.

19. Pichlmayr R, Weimann A, Klempnauer J, et al. Surgical treatment in proximal bile duct cancer. A single-center experience. Ann Surg. 1996; 224:628–638. PMID: 8916878.

20. Klempnauer J, Ridder GJ, von Wasielewski R, et al. Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J Clin Oncol. 1997; 15:947–954. PMID: 9060532.

21. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer. 2002; 95:1685–1695. PMID: 12365016.

22. Pitt HA, Nakeeb A, Abrams RA, et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg. 1995; 221:788–797. PMID: 7794082.

23. Borghero Y, Crane CH, Szklaruk J, et al. Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol. 2008; 15:3147–3156. PMID: 18754070.

24. Gwak HK, Kim WC, Kim HJ, et al. Extrahepatic bile duct cancers: surgery alone versus surgery plus postoperative radiation therapy. Int J Radiat Oncol Biol Phys. 2010; 78:194–198. PMID: 19910130.

25. Ben-David MA, Griffith KA, Abu-Isa E, et al. External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2006; 66:772–779. PMID: 17011452.

26. Oh D, Lim do H, Heo JS, et al. The role of adjuvant radiotherapy in microscopic tumor control after extrahepatic bile duct cancer surgery. Am J Clin Oncol. 2007; 30:21–25. PMID: 17278890.

27. Kim S, Kim SW, Bang YJ, et al. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys. 2002; 54:414–419. PMID: 12243816.